secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jounce Therapeutics, Inc. (—)
CIK:        0001640455
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001640455-23-000003
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Jounce Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance
--------------------------------------------------------------------------------

- Received Nasdaq deficiency letter on Dec 29, 2022; bid price below $1.00 for 30 consecutive business days.
- Has until June 27, 2023 to regain compliance; closing bid must be ≥$1.00 for 10 consecutive business days.
- May consider reverse stock split or transfer to Nasdaq Capital Market if not compliant by deadline.
- Failure to regain compliance could lead to delisting; appeal rights exist but no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640455/000164045523000003/0001640455-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640455/000164045523000003/jnce-20221229.htm
  HTML page:      https://secwatch.observer/filing/0001640455-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer